Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paroxetine (Paxil) in children and adolescents with major depressive disorder
2015-004905-17Phase 4
- Sponsor
- GSK
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in major depressive disorder (MDD) comparing Paroxetine (Paxil) with Placebo (2 arms). Primary endpoint: Change from baseline in CDRS-R total score at Week 8.
02
Drugs
paroxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2015-004905-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004905-17.